Merck KGaA to Acquire Bio-Techne for $11 Billion
Merck KGaA announced the acquisition of Bio-Techne for $11 billion in cash, offering $73 per share, a 24% premium over the closing price. The deal is expected to close in the first half of 2027.
Key Numbers
Merck KGaA has announced its acquisition of Bio-Techne, a U.S. supplier of lab tools, for $11 billion in cash. The offer of $73 per share represents a 24% premium over Bio-Techne's closing price on Wednesday, June 25, 2026. The transaction is expected to close in the first half of 2027.
Deal Details
| Item | Value |
|---|---|
| Deal Value | $11 billion |
| Price per Share | $73 cash |
| Premium | 24% over June 25, 2026 close |
| Payment Method | All cash |
| Expected Close | H1 2027 |
Rationale
The acquisition aims to strengthen Merck's position in the specialized lab tools market, leveraging Bio-Techne's extensive customer base in life sciences research and diagnostics. It will also expand Merck's life science product portfolio.
Regulatory Challenges
The deal is expected to face antitrust reviews in the U.S. and Europe due to the size and overlap of the companies' businesses. However, analysts believe approval chances are high given the competitive nature of the sector.
Impact on Stocks
No immediate reaction from Merck's stock (MRK) has been observed, but Bio-Techne's shares are expected to rise toward the offer price. Investors are watching regulatory developments closely.
Frequently Asked Questions
Found this useful? Share it